Detail of "57248-88-1"

CAS Number:
57248-88-1
Name:
Phosphonicacid, P,P'-(3-amino-1-hydroxypropylidene)bis-, sodium salt (1:2)
Superlist Name:
Pamidronate disodium salt
Molecular Structure:
Formula:
C₃H₉NNa₂O₇P₂
Molecular Weight:
279.03
Synonyms:
Phosphonicacid, (3-amino-1-hydroxypropylidene)bis-, disodium salt (9CI);3-Amino-1-hydroxypropane-1,1-diphosphonicacid disodium salt;APD;Aminomux;Aredia;CGP 23339A;CGP 23339AE;Disodium3-amino-1-hydroxypropane-1,1-diphosphonate;Pamidronic acid disodium salt;
EINECS:
260-647-1
Melting Point:
300 °C
Boiling Point:
658.7 °C at 760 mmHg
Flash Point:
352.2 °C
Solubility:
28 mg/mL in water
Appearance:
White Crystals
Hazard Symbols:
Xn
Risk Codes:
22-48-41-37/38-20/21/22
Safety:
22-26-36/37/39-45 Details

Supplier Location
Supplier Location
- China (Mainland)(16)
- India(5)
- United States(2)
- Hong Kong(1)
Business Type
Business Type
- Lab/Research institutions(1)
- Manufacturers(4)
- Trading Company(17)
Certificates
Certificates
- ISO(1)
- Production License(1)
Exhibitions
Exhibitions
- Informex USA
- CPhI China

Display：

Please post your buying leads,so that our qualified suppliers will soon contact you!
*Required Fields

Influence of treatment with APD-bisphosphonate on the bone lesions in mouse 5T2 multiple myeloma: Influence of treatment with APD-bisphosphonate on the bone lesions in mouse 5T2 multiple myeloma. Radl, Jiri; Croese, Jan W.; Zurcher, Chris; Van den Enden-Vieveen, Margit H. M.; Brondijk, Roelfien J.; Kazil, Marketa; Haaijman, Joost; Reitsma, Pieter H.; Bijvoet, Olav L. M. (Inst. Exp. Gerontol., TNO, Rijswijk, Neth.). Cancer (Philadelphia), 55(5), 1030-40 (English) 1985. CODEN: CANCAR. ISSN: 0008-543X. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) The effects of the treatment of multiple myeloma (MM) with (3-amino-1-hydroxypropylidene) 1,1-bisphosphonate (APD bisphosphonate) [57248-88-1] on bone destruction, the dissemination pattern of the MM, and toxicity for normal and malignant cells were investigated in an animal model, the 5T2 MM. This mouse MM very closely resembles the human disease, including the typical bone lesions. Treatment of the 5T2 MM with APD bisphosphonate protected the mice against bone loss. It seemed that the treatment with APD bisphosphonate not only diminished the bone destruction by the MM but also led to the formation of new bone in already-affected bone tissue. The growth pattern of the MM was not substantially influenced by the treatment, even though there was an indication that the compd. exerted some cytotoxic effect on the MM cells.

Preparation for treatment of disorders of calcium metabolism: Preparation for treatment of disorders of calcium metabolism. Schmidt-Dunker, Manfred (Henkel K.-G.a.A., Fed. Rep. Ger.Chemical with cas number 9007-12-9 also plays role.).Some commonly used reagents like 9007-12-9 is used in this experiment. Pat. Specif. (Aust.) AU 538311 B2 9 Aug 1984, 40 pp. (English). (Australia). CODEN: ALXXAP. CLASS: IC: A61K031-19; A61K031-66; A61K031-675. APPLICATION: AU 81-65960 2 Jan 1981. DOCUMENT TYPE: Patent CA Section: 63 (Pharmaceuticals) Section cross-reference(s): 1 Pharmaceuticals for the treatment of diseases characterized by excessive pathol. rates of Ca metab. such as Pagets disease, hypercalcemia, and osteoporosis contain combinations of reduced doses of calcitonin [9007-12-9] with aminophosphonic acids, complex-forming carboxyphosphonates and/or) cyclohexanehexacarboxylic acid. A patient suffering from Pagets disease was treated daily with 2 dosage units, capsules contg. 0.5 mg synthetic human calcitonin and 350 mg di-Na 3-amino-1-hydroxypropane-1,1-diphosphonate [57248-88-1]. The biochem. control values dropped to a considerable extent after 4 wk. The pain in bones disappeared, alk. phosphatase and urine hydroxyproline were normal after 4 mo, the histol. condition of the bones returned to normal, and there was no demineralized osteoid tissue. ..